Dental Bone Graft Substitute Market Size, Share & Trends Analysis | Europe | 2025-2031 | Includes: Allografts, Xenografts, Synthetics, Dental Growth Factors & Dental Barrier Membranes

Description

List of Tables

The European dental bone graft substitute and other biomaterials market was valued at nearly €355 million in 2024. It is projected to grow at a compound annual growth rate of 3.4 percent to reach nearly €450 million in 2031.

This report covers dental bone graft substitutes (DBGSs), dental growth factors, dental barrier membranes (DBMs), local antimicrobial periodontal treatment, and dental soft tissue regeneration. Within DBGSs, the analysis includes allografts, xenografts, and synthetics, while autografts are excluded since they are harvested from the patient and are not sold commercially. The dental growth factor category includes sales of Straumann Group's Emdogain(R). The DBM market is split into resorbable and non-resorbable segments. Dental soft tissue regeneration is segmented into regenerative products and wound care products.

The market's trajectory reflects Europe's aging population, growing implant placement volumes, and broader awareness of regenerative dentistry among clinicians and patients. Demand is tempered by the region's stringent allograft protocols, continued use of autograft materials in selected countries, and gradual improvements in baseline oral health that reduce the long-term pool of fully edentulous patients. Even with these headwinds, steady adoption of xenograft and synthetic materials, plus expanding usage of barrier membranes and soft tissue products, is expected to support consistent market growth through 2031.

Market Overview

Regenerative dental materials are fundamental to modern implant and periodontal practice in Europe. DBGSs support socket preservation, sinus augmentation, ridge augmentation, and periodontal defect repair. Dental barrier membranes guide tissue regeneration and protect graft sites. Local antimicrobial periodontal treatments address residual bacterial burden, and soft tissue products promote closure and healing around implants and grafts.

The demand profile varies across Western, Northern, Central, and Southern Europe. Countries with mature implant markets and strong private-pay segments show higher penetration of xenografts and resorbable collagen membranes. In parallel, synthetic biomaterials remain important where cultural preferences limit animal-derived products or where procurement emphasizes cost stability. Allografts have grown in selected markets due to better processing techniques and quality assurance, though overall European uptake trails the United States because of regulation and tissue bank consolidation.

Aging demographics remain the dominant structural driver. By 2030, individuals 65 and older are expected to represent about a quarter of Europe's total population. Older adults experience higher rates of tooth loss, alveolar bone resorption, and periodontitis, which increases the need for grafting prior to implant placement. At the same time, widespread preventive dentistry and more routine hygiene compliance have improved dentition for many cohorts, which moderates long-run growth in fully edentulous cases. The net effect still favors steady expansion of regenerative procedures aligned with implants and complex periodontal therapy.

Market value reflects not only procedure volumes but also material mix, case complexity, and training intensity. Premium xenografts and resorbable membranes are used routinely in two-stage and immediate implant workflows. Synthetics add flexibility for practices that prefer non-animal materials or that need specific resorption profiles. Soft tissue products and wound care items support closure, especially in thin biotype cases and when clinicians need extra protection during early healing.

Market Drivers

Prevalence of oral disease

Global burden-of-disease analyses indicate large and rising totals of severe periodontitis and edentulism. In Western Europe, about 60 million people were living with severe periodontitis in 2021 with 5 million incident cases, and projections suggest a further rise in both prevalence and incidence by 2050. For edentulism, Western Europe reported 37 million cases in 2021, moving toward 48 million by 2050, with incidence also increasing over the same period. These burdens translate into sustained clinical demand for regenerative intervention, whether to preserve extraction sockets, build vertical or horizontal ridge volume, or stabilize soft tissues prior to definitive prosthetics.

Aging population

By 2030, people aged 65+ are expected to comprise about 25 percent of Europe's population. Age-related bone remodeling and the higher prevalence of systemic risk factors like diabetes and osteoporosis increase the likelihood of grafting before or during implant therapy. As a result, DBGSs and membranes will continue to be used at higher rates in older patients who want fixed restorations.

Greater consumer awareness and portfolio bundling

As implants gain popularity, implant vendors and distributors are bundling regenerative portfolios alongside implant lines. Dedicated sales teams and clinical education programs have raised awareness of guided bone regeneration and the role of membranes in predictable outcomes. This go-to-market model supports pull-through demand for xenografts, synthetics, and resorbable collagen membranes as standard adjuncts to implant placement.

Growing acceptance of allograft materials

Earlier concerns about disease transmission have eased as manufacturers implement validated processing, traceability, and quality assurance. With clearer messaging around safety and regulatory compliance, more clinicians are considering allograft options for specific defect types where handling and remodeling profiles fit their technique. Although allograft use remains lower than in the United States, acceptance is improving in centers with strong tissue bank partnerships and structured training.

Market Limiters

Improved oral health

Routine hygiene, fluoridation policies, and preventive care have reduced the long-term incidence of complete edentulism. As older cohorts retain more natural dentition, the absolute number of full-arch implant reconstructions and extensive ridge augmentations is moderated, even as single-tooth and segmental sites remain active.

Continued reliance on autograft materials

Autograft harvesting persists in parts of Europe, especially where surgeon preference and reimbursement frameworks favor intraoral donor sites. This is most evident in markets like France, where the DBGS segment is comparatively underdeveloped. Autograft usage displaces commercial DBGS demand in horizontal and vertical augmentation cases, limiting unit growth for allografts, xenografts, and synthetics.

Stringent allograft protocols and tissue bank consolidation

European regulation of human tissue products is strict. Over the last decade, tighter rules increased operating costs for tissue banks, leading to closures in several countries. In Portugal, for example, allograft distribution ceased when tissue banks could not reorganize under updated requirements. The result is a smaller pool of approved suppliers, constrained product choice, and an ongoing shift to autografts or cost-effective synthetics, which can cap average selling prices and dampen allograft penetration.

Price sensitivity in parts of Central and Southern Europe

Private-pay dynamics dominate many implant cases. In regions where out-of-pocket spending is high, clinicians may favor synthetic materials with attractive value profiles or limit membrane usage to the most clinically necessary cases. This keeps premium mix growth modest in price-sensitive markets.

Market Coverage and Data Scope

Quantitative coverage: Market size, market shares, forecasts, growth rates, units sold, and average selling prices.
Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles, product portfolios, disruptive technologies, and disease overviews that shape regenerative demand.
Time frame: Base year 2024, forecasts to 2031, historical data 2021-2023.
Data sources: Primary interviews with industry leaders, government and regulatory data, hospital and private practice inputs, import and export records, and the iData Research internal database.
Method note: Revenue modeled as units multiplied by ASP, validated with procedure counts, case mix, and distributor feedback.

Markets Covered and Segmentation

Dental Bone Graft Substitutes (DBGSs)

Type: Allografts, xenografts, synthetics
Application: Socket preservation, sinus augmentation, ridge augmentation, periodontal application

Dental Growth Factor

Includes Emdogain(R) sales

Dental Barrier Membranes (DBMs)

Type: Resorbable membranes, non-resorbable membranes

Local Antimicrobial Periodontal Treatment

Dental Soft Tissue Wound Care

Type: Regeneration products, dental wound care products such as plug, tape, and foam

For every segment, the report presents market values, unit sales, ASPs, growth rates, and company shares, with historical data to 2021 and forecasts to 2031.

Competitive Analysis

Geistlich remained the leading competitor in the total European DBGS and biomaterials market in 2024. Its dominance stems from leadership in both the DBGS and DBM segments. In DBGS, Geistlich holds a majority share in xenografts, supported by the well-established Bio-Oss(R) product line. In membranes, Bio-Gide(R) is widely used as a resorbable collagen barrier due to its handling, biocompatibility, and remodeling behavior. The brand's clinical legacy, training footprint, and long record of documentation continue to reinforce preference among periodontists and implant surgeons.

botiss biomaterials held the second-largest share of the total market in 2024. A key strength is its strategic partnership with Straumann Group, which holds a 30 percent stake in botiss. This relationship aligns botiss regenerative products with Straumann's leadership in implants across Europe, improving access and co-selling effectiveness. Flagship products include cerabone(R) (xenograft) and maxgraft(R) (allograft), which give clinicians a portfolio that spans material preferences and indications.

PerioChip(R) was the leading competitor in the European local antimicrobial periodontal treatment market in 2024, placing third overall in the total DBGS and biomaterials landscape. Distribution is supported by an extensive network. In Europe, Dexcel Pharma markets PerioChip(R) through subsidiaries and partners in Germany, the U.K., Benelux, Austria, and other countries. Additional distribution is provided by Curaden Healthcare in Italy and Karr Denta in Switzerland. PerioChip(R)'s role in reducing bacterial load within periodontal pockets complements regenerative and maintenance protocols, which helps anchor its adoption across specialist practices.

Other regional and local suppliers compete in synthetic DBGS, non-resorbable membranes, and selected soft tissue products. However, the market remains concentrated around companies that can support education, clinical evidence, and reliable logistics across multiple European countries with different regulatory expectations.

Technology and Practice Trends

Material choice by indication: Clinicians often combine xenografts for space maintenance with allografts or synthetics for remodeling speed, depending on case goals and timing for implant placement.
Shift to resorbable membranes: Resorbable collagen membranes remain the first choice for most GBR procedures due to ease of use and avoidance of removal surgery. Non-resorbable membranes retain a role in complex vertical augmentation when stronger space maintenance is needed.
Barrier fixation and stability: Tack systems, suturing techniques, and contouring advances reduce micromotion, improve soft tissue management, and increase predictability in challenging defects.
Soft tissue emphasis: Greater attention to thickening peri-implant soft tissue has increased the use of soft tissue graft substitutes and wound care materials in thin biotype patients or when harvesting autogenous connective tissue is not preferred.
Training, digital planning, and workflows: Digital planning tools and education programs emphasize defect classification, graft selection, and timing. Consistent protocols allow multi-site organizations and referral networks to standardize outcomes.
Quality systems and traceability: Documentation, batch tracking, and sterility assurance support clinician confidence and compliance with national guidelines, especially in allograft use.

Geography

The analysis covers the European Union.

Why This Report

Where are the largest and fastest-growing opportunities across xenografts, allografts, synthetics, barrier membranes, and soft tissue products.

How the aging population and oral disease burden will shape procedure demand through 2031.

How stringent allograft regulations and tissue bank consolidation affect product access and pricing in different European markets.

Which education and portfolio bundling strategies are most effective for implant and regenerative pull-through.

How leaders such as Geistlich, botiss biomaterials, and PerioChip(R) are positioned, and what their portfolios imply for competition in DBGS and membranes.

Where autograft reliance will continue to limit DBGS adoption, and how synthetics and targeted membrane selection can bridge clinical needs.

What technology and workflow trends will improve predictability in vertical and horizontal augmentation, socket preservation, and soft tissue management.

How to align training, inventory, and case documentation to standardize results across multi-site practices and referral networks.

The European Dental Bone Graft Substitute and Other Biomaterials Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail. Use it to quantify demand, plan portfolio strategy, guide regional market entry, and prioritize education that supports predictable regenerative outcomes.

Product Code: iDATA_EUDBGS25_MS

TABLE OF CONTENT

Table Of Contents

List Of Figures

List Of Charts

European Dental Bone Graft Substitute And Other Biomaterials Market Overview

Competitive Analysis

Market Developments

Market Trends

Procedure Segmentation

Market Segmentation

Key Report Updates

Version History

Research Methodology

Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems And Perform Secondary Research
Step 3: Preparation For Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast And Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review And Market Release
Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

European Dental Bone Graft Substitute And Other Biomaterials Market Overview

3.1 Introduction
- 3.1.1 Applications Of Dental Bone Graft Substitutes
  - 3.1.1.1 Dental Implant Procedures
  - 3.1.1.2 Periodontal Procedures
- 3.1.2 Types Of Dental Bone Graft Substitutes
  - 3.1.2.1 Allografts
  - 3.1.2.2 Demineralized Bone Matrix Allografts
  - 3.1.2.3 Xenografts
  - 3.1.2.4 Synthetics
- 3.1.3 Dental Growth Factor Products
- 3.1.4 Dental Membranes
- 3.1.5 Antimicrobial Periodontal Treatment
- 3.1.6 Dental Soft Tissue Regeneration
3.2 Currency Exchange Rate
3.3 Market Overview & Trend Analysis
3.4 Drivers And Limiters
- 3.4.1 Market Drivers
- 3.4.2 Market Limiters
3.5 Competitive Market Share Analysis
3.6 Mergers And Acquisitions

Country Profiles

4.1 Introduction
- 4.1.1 Population
- 4.1.2 Gdp Per Capita
- 4.1.3 Price Index
4.2 Germany
4.3 France
4.4 United Kingdom
4.5 Italy
4.6 Spain
4.7 Benelux
4.8 Scandinavia
4.9 Austria
4.10 Switzerland
4.11 Portugal

Procedure Numbers

5.1 Europe Tooth Loss Statistics
- 5.1.1 Dental Bone Grafting Procedures
- 5.1.2 Dental Implant Procedures And Dbgs Penetration Rates
- 5.1.3 Dental Bone Grafting Procedures By Application

Dental Bone Graft Substitute Market

6.1 Introduction
- 6.1.1 Autografts
- 6.1.2 Allografts
  - 6.1.2.1 Mineralized Allografts
  - 6.1.2.2 Demineralized Bone Matrix Allografts
- 6.1.3 Xenografts
- 6.1.4 Synthetics
6.2 Market Overview
6.3 Market Analysis And Forecast
- 6.3.1 Total Dental Bone Graft Substitute Market
- 6.3.2 Allograft Market By Segment
  - 6.3.2.1 Mineralized Allograft Market
  - 6.3.2.2 Demineralized Bone Matrix Allograft Market
- 6.3.3 Xenograft Market
- 6.3.4 Synthetic Market
- 6.3.5 Dental Bone Graft Substitute Unit Sales By Procedure Type
  - 6.3.5.1 Socket Preservation
  - 6.3.5.2 Sinus Augmentation
  - 6.3.5.3 Ridge Augmentation
  - 6.3.5.4 Periodontal Application
6.4 Drivers And Limiters
- 6.4.1 Market Drivers
- 6.4.2 Market Limiters
6.5 Competitive Market Share Analysis

Dental Growth Factor Market

7.1 Introduction
7.2 Market Analysis And Forecast
7.3 Drivers And Limiters
- 7.3.1 Market Drivers
- 7.3.2 Market Limiters

Dental Barrier Membrane Market

8.1 Introduction
8.2 Market Overview
8.3 Market Analysis And Forecast
- 8.3.1 Total Dental Barrier Membrane Market
- 8.3.2 Resorbable Dental Barrier Membrane Market
- 8.3.3 Non-Resorbable Dental Barrier Membrane Market
8.4 Unit Analysis
- 8.4.1 Dental Barrier Membrane Units Sold By Size
  - 8.4.1.1 Resorbable Dental Barrier Membrane Units Sold By Size
  - 8.4.1.2 Non-Resorbable Dental Barrier Membrane Units Sold By Size
8.5 Drivers And Limiters
- 8.5.1 Market Drivers
- 8.5.2 Market Limiters
8.6 Competitive Market Share Analysis

Local Antimicrobial Periodontal Treatment Market

9.1 Introduction
9.2 Market Analysis And Forecast
9.3 Drivers And Limiters
- 9.3.1 Market Drivers
- 9.3.2 Market Limiters
9.4 Competitive Market Share Analysis

Dental Soft Tissue Regeneration Market

10.1 Introduction
10.2 Market Overview
10.3 Market Analysis And Forecast
- 10.3.1 Dental Soft Tissue Regeneration Market
- 10.3.2 Dental Wound Care Market
  - 10.3.2.1 Plug Dental Wound Care Market
  - 10.3.2.2 Tape Dental Wound Care Market
  - 10.3.2.3 Foam Dental Wound Care Market
10.4 Drivers And Limiters
- 10.4.1 Market Drivers
- 10.4.2 Market Limiters
10.5 Competitive Market Share Analysis

Abbreviations